fbpx Partnership Opportunities - Plus Therapeutics (PSTV)

Let’s help patients battle cancer, together.

We fully understand that building productive relationships with business, technology, development, and supplier partners is essential to fulfilling our short- and long-term goals for our company – and for the future of healthcare. Every collaborative effort takes us one step closer to making new discoveries, advancing and expanding our pipeline, achieving commercial success and ultimately, establishing a higher bar in radiation oncology.

Value Creation

We aim to benefit from each other’s value and expertise across a variety of capabilities.

Proprietary & Supportive Technologies

Product & Clinical Development

Manufacturing & Analytical Testing

Network of World-renowned Research & Cancer Institutions

Proprietary & Supportive Technologies

Product & Clinical Development

Manufacturing & Analytical Testing

Network of World-renowned Research & Cancer Institutions

Proprietary & Supportive Technologies

Product & Clinical Development

Manufacturing & Analytical Testing

Network of World-renowned Research & Cancer Institutions

Licensing Opportunities

We are developing multiple drug candidates in the radiotherapy space – a market experiencing significant deal activity and R&D investment, and that is projected to grow significantly over the next 5 years.

186RNL (Rhenium-186 NanoLiposome)

A patented, targeted radiotherapeutic for brain and CNS cancers

Comprised of a BMEDA-chelated Rhenium-186 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome

Currently being evaluated in U.S. Phase 1 clinical trials: ReSPECT-GBM (supported by NIH/NCI) for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases

188RNL-BAM (Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere)

A next-generation radioembolization therapy for the treatment of primary and secondary liver cancers

Comprised of a BMEDA-chelated Rhenium-188 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome and loaded into a biodegradable alginate 50-micrometer microsphere

186RNL (Rhenium-186 NanoLiposome)

A patented, targeted radiotherapeutic for brain and CNS cancers

Comprised of a BMEDA-chelated Rhenium-186 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome

Currently being evaluated in U.S. Phase 1 clinical trials: ReSPECT-GBM (supported by NIH/NCI) for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases

188RNL-BAM (Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere)

A next-generation radioembolization therapy for the treatment of primary and secondary liver cancers

Comprised of a BMEDA-chelated Rhenium-188 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome and loaded into a biodegradable alginate 50-micrometer microsphere

186RNL (Rhenium-186 NanoLiposome)

A patented, targeted radiotherapeutic for brain and CNS cancers

Comprised of a BMEDA-chelated Rhenium-186 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome

Currently being evaluated in U.S. Phase 1 clinical trials: ReSPECT-GBM (supported by NIH/NCI) for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases

188RNL-BAM (Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere)

A next-generation radioembolization therapy for the treatment of primary and secondary liver cancers

Comprised of a BMEDA-chelated Rhenium-188 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome and loaded into a biodegradable alginate 50-micrometer microsphere

Supplier and vendor partnerships.

We are always looking for new suppliers and vendors to help us in the areas of raw materials, product and clinical development, analytical chemistry, manufacturing, quality, regulatory affairs, and industry partnerships.

Current Principal Contract Development & Manufacturing Partners

Reach out to discuss various partnership
approaches
and pathways.